RPTX vs. DMAC, PDSB, SGMT, SYRS, FGEN, ACET, AMLX, RGLS, NVCT, and INCR
Should you be buying Repare Therapeutics stock or one of its competitors? The main competitors of Repare Therapeutics include DiaMedica Therapeutics (DMAC), PDS Biotechnology (PDSB), Sagimet Biosciences (SGMT), Syros Pharmaceuticals (SYRS), FibroGen (FGEN), Adicet Bio (ACET), Amylyx Pharmaceuticals (AMLX), Regulus Therapeutics (RGLS), Nuvectis Pharma (NVCT), and InterCure (INCR). These companies are all part of the "pharmaceutical preparations" industry.
Repare Therapeutics (NASDAQ:RPTX) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, community ranking, dividends, profitability and institutional ownership.
DiaMedica Therapeutics has lower revenue, but higher earnings than Repare Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks.
DiaMedica Therapeutics received 56 more outperform votes than Repare Therapeutics when rated by MarketBeat users. Likewise, 62.07% of users gave DiaMedica Therapeutics an outperform vote while only 60.71% of users gave Repare Therapeutics an outperform vote.
Repare Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.
Repare Therapeutics currently has a consensus price target of $17.33, suggesting a potential upside of 391.03%. DiaMedica Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 120.82%. Given Repare Therapeutics' higher possible upside, research analysts clearly believe Repare Therapeutics is more favorable than DiaMedica Therapeutics.
85.1% of Repare Therapeutics shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 28.5% of Repare Therapeutics shares are held by company insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
DiaMedica Therapeutics has a net margin of 0.00% compared to Repare Therapeutics' net margin of -46.69%. Repare Therapeutics' return on equity of -19.81% beat DiaMedica Therapeutics' return on equity.
In the previous week, DiaMedica Therapeutics had 1 more articles in the media than Repare Therapeutics. MarketBeat recorded 4 mentions for DiaMedica Therapeutics and 3 mentions for Repare Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.31 beat Repare Therapeutics' score of 0.69 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.
Summary
Repare Therapeutics and DiaMedica Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Repare Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Repare Therapeutics Competitors List
Related Companies and Tools
